Sanofi

SNY · XNAS

CIK 1121404fmd_137W4N5WBGE2EM7YYG0HW0FT79Manufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2015 to Dec 31, 2025, 18 periods

Income Statement · Annual · Millions · EUR
Line item	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cost of revenue	10,701	11,613	11,435	11,979	12,159	12,255	11,882	12,628	13,205	13,049
Gross profit	23,995	24,608	24,242	25,652	25,212	26,920	28,679	28,990	31,081	33,667
Research and development	5,172	5,472	5,894	6,020	5,530	5,692	6,501	6,507	7,394	7,842
Selling, general and administrative	9,478	10,072	9,859	9,884	9,391	9,555	8,739	8,933	9,183	9,543
Operating income	6,531	5,804	4,676	3,051	14,113	8,126	10,162	6,960	7,252	6,344
Interest expense	924	420	435	440	388	368	430	1,293	1,073	563
Income tax expense	1,325	1,722	481	121	1,807	1,558	1,909	1,017	1,204	1,043
Net income from continuing operations	4,486	3,894	4,423	2,886	12,330	6,279	8,083	5,098	5,554	4,977
Net income	4,709	8,416	4,306	2,754	12,294	6,223	8,371	5,400	5,560	7,813
Net income to common shareholders	(4,709)	(8,416)	4,306	2,754	12,294	6,223	8,371	5,400	5,560	7,813